Repare axes 75% of staff as it hunkers down on two early stage assets
Repare Therapeutics, a clinical-stage precision oncology company, has announced a significant restructuring that includes laying off 75% of its workforce as it refocuses on two early-stage assets8. Here are the key details:
Restructuring and Layoffs
- Repare is reducing its headcount by 75%, affecting approximately 134 employees based on its February 2024 employee count of 1798.
- The layoffs are expected to be completed by the fourth quarter of 20258.
- Chief Medical Officer Maria Koehler, M.D., Ph.D. will be departing as part of the restructuring8.
Financial Impact
- The company expects to pay out around $7.3 million in severance costs8.
- An additional $1.4 million will be allocated for one-time employee retention costs for key executives8.
- The reduced headcount is projected to save Repare about $21 million annually8.
Pipeline Prioritization
Repare is refocusing its efforts on two Phase I clinical programs:
1. RP-1664:
A PLK4 inhibitor being evaluated as a monotherapy in adolescent patients with TRIM37-high solid tumors8.
2. RP-3467:
A Polθ ATPase inhibitor being studied alone and in combination with olaparib in various cancer types8.
The company has deprioritized other assets, including a combination of lunresertib and camonsertib (Lunre+Camo)8.
Rationale and Outlook
CEO Lloyd Segal stated that the restructuring aims to achieve near-term inflection points for the two prioritized Phase I assets, which have the potential to address significant unmet patient needs and deliver important catalysts in 20258. The company believes these changes will provide a foundation for meaningful value creation and extend its cash runway5.
Sources:
5. https://www.biospace.com/biospace-layoff-tracker
8. https://www.fiercebiotech.com/biotech/repare-unveils-scale-layoffs-75-staff-and-chief-medical-officer-heading-exit